BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma

Research output: Contribution to journalReview article

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)1351-1353
Number of pages3
JournalImmunotherapy
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2016

Keywords

  • Bim
  • immunotherapy
  • melanoma
  • PD-1
  • PD-L1
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this